Doctor Now Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
42
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$1.01M
- Investors
-
17
Doctor Now General Information
Description
Developer of a healthcare application designed to offer telemedicine and drug delivery services. The company offers non-face-to-face medical treatment and prescription drug delivery services in Korea and remote consultation, enabling customers to manage their health by receiving accurate treatment anytime, anywhere, and receiving timely delivery of prescription drugs.
Contact Information
Website
www.doctornow.co.krCorporate Office
- 16th floor, 625 Teheran-ro
- Gangnam-gu
- Seoul
- South Korea
Corporate Office
- 16th floor, 625 Teheran-ro
- Gangnam-gu
- Seoul
- South Korea
Doctor Now Timeline
Doctor Now Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series B2) | 06-Nov-2025 | $1.01M | Completed | Generating Revenue | ||
| 7. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 6. Later Stage VC | 14-Nov-2024 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 21-Sep-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 16-Mar-2023 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 12-Oct-2021 | Completed | Generating Revenue | |||
| 2. Seed Round | 01-Jun-2021 | $1.78M | $1.78M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Doctor Now Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Doctor Now Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Doctor Now Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mirae Science and Technology | Venture Capital | Minority | ||
| Saehan Venture Capital | Venture Capital | Minority | ||
| DAYLI Partners | Venture Capital | Minority | ||
| HG Initiative | Impact Investing | Minority | ||
| Waterline Ventures | Venture Capital | Minority |
Doctor Now Acquisitions (1)
Doctor Now’s most recent deal was a Merger/Acquisition with Boosters Company. The deal was made on 01-Sep-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Boosters Company | 01-Sep-2022 | Merger/Acquisition | Clinics/Outpatient Services |
Doctor Now FAQs
-
When was Doctor Now founded?
Doctor Now was founded in 2019.
-
Where is Doctor Now headquartered?
Doctor Now is headquartered in Seoul, South Korea.
-
What is the size of Doctor Now?
Doctor Now has 42 total employees.
-
What industry is Doctor Now in?
Doctor Now’s primary industry is Clinics/Outpatient Services.
-
Is Doctor Now a private or public company?
Doctor Now is a Private company.
-
What is Doctor Now’s current revenue?
The current revenue for Doctor Now is .
-
How much funding has Doctor Now raised over time?
Doctor Now has raised $47.7M.
-
Who are Doctor Now’s investors?
Mirae Science and Technology, Saehan Venture Capital, DAYLI Partners, HG Initiative, and Waterline Ventures are 5 of 17 investors who have invested in Doctor Now.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
